Heterotopic Ossification Prophylaxis

计划入组 117 人 · 首次发布于 2021 年 4 月 30 日

Continuous Passive Motion Versus Heterotopic Ossification

计划入组 20 人 · 首次发布于 2023 年 6 月 15 日

Defining the Pathophysiology of Heterotopic Ossification: A Prospective Study

首次发布于 2021 年 4 月 30 日

RNA actuator therapeutic for hereditary angioedema(CAMP4 Therapeutics)

Palovarotene

C₂₇H₃₀N₂O₂

RNA actuator therapeutic (hereditary angioedema)

The Cooper Health System, A New Jersey Non-Profit Corporation

United States

REPLIGEN CORPORATION

United States

EMCURE PHARMACEUTICALS LIMITED

United Arab Emirates

āshibio Licenses Vantictumab for Rare Bone Disease ADO2 in Strategic Pipeline Expansion

āshibio Doses First Patient in Phase 2/3 Trial of Andecaliximab for Fibrodysplasia Ossificans Progressiva

FDA Grants Priority Review to Garetosmab for Ultra-Rare Bone Disease Fibrodysplasia Ossificans Progressiva